SI-BONE, Inc. reported results for the quarter ended 2026, with revenue of $56.01M, an improvement versus $48.63M a year earlier, and a reduced net loss and loss per share compared with the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$56.01M$48.63M15.2% | Net income²($4.09M)($6.15M)33.6% | Diluted EPS³($0.09)($0.14)35.7% |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”.
Business Highlights
- Revenue growth YTD of 13.2% to $108.6M was driven by a 12.3% increase in procedure volume and broader adoption of SI-BONE’s therapies.
- Channel shift toward ASCs and OBLs continued, with these sites accounting for over 35% of U.S. sacroiliac joint procedures, supported by expanded sales coverage.
- U.S. commercial expansion included growth to more than 175 direct sales representatives and increased use of third‑party agents to improve case coverage.
- R&D investment and product development momentum: three platform technologies have been designated FDA Breakthrough Devices.
- Operational initiatives included higher revenue per territory manager (approximately $2.2M TTM) and increased inventory ahead of new product launches.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.